| Name | Title | Contact Details |
|---|---|---|
Greg Zindulka |
director of r&d | Profile |
Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.
At Runatek, were ending the Opioid Crisis with innovative technology
Dynarex Corporation is a Orangeburg, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Womens International Pharmacy is a Madison, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.